Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk.

Thounaojam MC, Dudimah DF, Pellom ST, Uzhachenko RV, Carbone DP, Dikov MM, Shanker A. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk. Oncotarget. 2015 Oct 20; 6(32):32439-55.

View in: PubMed

subject areas

Animals
Antineoplastic Agents
Basic Helix-Loop-Helix Transcription Factors
Breast Neoplasms
CD8-Positive T-Lymphocytes
Cell Cycle Proteins
Cell Line, Tumor
Dose-Response Relationship, Drug
Female
Genes, ras
Granzymes
Homeodomain Proteins
Humans
Kidney Neoplasms
Lung Neoplasms
Lymphocytes, Tumor-Infiltrating
Mice, Inbred BALB C
Mice, Transgenic
Mutation
Neuronal Ceroid-Lipofuscinoses
NF-kappa B
Pore Forming Cytotoxic Proteins
Receptors, Notch
Signal Transduction
T-Box Domain Proteins
Tumor Escape
Tumor Suppressor Protein p53

authors with profiles

Anil Shanker

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support